Sort
10,766 grants matching “checkpoint inhibitor”
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
$1,004,844Brian J Druker · Oregon Health & Science University · U01 · FY2018 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
$1,004,844Brian J Druker · Oregon Health & Science University · U01 · FY2020 · CA
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies
$1,004,844Brian J Druker · Oregon Health & Science University · U01 · FY2021 · CA
Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$1,004,278Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2019 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,004,241Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2022 · CA
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
$1,004,186Scott Budd Winram · Cynvec, Llc · R44 · FY2017 · CA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$1,004,043Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Metabolic basis of B cell lineage leukemia relapse
$1,003,965Markus Mãschen · Beckman Research Institute/City Of Hope · R35 · FY2019 · CA
Determinants of response to cancer immunotherapy
$1,002,984Lawrence Fong · Fred Hutchinson Cancer Center · R35 · FY2024 · CA
Exosomes as carriers of cancer therapeutics
$1,002,901Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2025 · CA
Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response
$1,002,287Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2024 · CA
Metabolic basis of B cell lineage leukemia relapse
$1,002,111Markus Mãschen · Yale University · R35 · FY2021 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$1,001,898Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2019 · CA
Identification of radiosensitizers for prostate cancer
$1,001,043Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
SIRPant Technology for anti-Cancer Immunity
$1,000,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2023 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2020 · CA
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2022 · CA
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2021 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
Cancer Immunologic Data Commons (CIDC) Supplement Request
$1,000,000Ethan Cerami · Dana-Farber Cancer Inst · U24 · FY2022 · CA
SIRPant Technology for anti-Cancer Immunity
$999,999Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA
Development of GIFT4: a B cell focused immunotherapy for cancer
$999,997Paul Guyre · Celdara Medical, Llc · R44 · FY2018 · CA
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
$999,960Tina Garyantes · Linnaeus Therapeutics Inc · R44 · FY2025 · CA